|Vector Type||Mammalian Expression Vector|
|Expression Method||Constiutive, Stable / Transient|
|Selection In Mammalian Cells||Hygromycin|
A myc tag can be used in many different assays that require recognition by an antibody. If there is no antibody against the studied protein, adding a myc-tag allows one to follow the protein with an antibody against the Myc epitope. Examples are cellular localization studies by immunofluorescence or detection by Western blotting.
The peptide sequence of the myc-tag is: N-EQKLISEEDL-C (1202 Da). It can be fused to the C-terminus and the N-terminus of a protein. It is advisable not to fuse the tag directly behind the signal peptide of a secretory protein, since it can interfere with translocation into the secretory pathway.
|Human HRAS ORF mammalian expression plasmid, C-GFPSpark tag||HG12059-ACG|
|Human HRAS ORF mammalian expression plasmid, C-OFPSpark / RFP tag||HG12059-ACR|
|Human HRAS ORF mammalian expression plasmid, C-Flag tag||HG12059-CF|
|Human HRAS ORF mammalian expression plasmid, C-His tag||HG12059-CH|
|Human HRAS ORF mammalian expression plasmid, C-Myc tag||HG12059-CM|
|Human HRAS ORF mammalian expression plasmid, C-HA tag||HG12059-CY|
|Human HRAS Gene cDNA clone plasmid||HG12059-G|
|Human HRAS ORF mammalian expression plasmid, N-Flag tag||HG12059-NF|
|Human HRAS ORF mammalian expression plasmid, N-His tag||HG12059-NH|
|Human HRAS ORF mammalian expression plasmid, N-Myc tag||HG12059-NM|
|Human HRAS ORF mammalian expression plasmid, N-HA tag||HG12059-NY|
|Human HRAS natural ORF mammalian expression plasmid||HG12059-UT|
|Learn more about expression Vectors|
HRas, also known as HRAS, belongs to the small GTPase superfamily, Ras family and is widely expressed. It functions in signal transduction pathways. HRas can bind GTP and GDP, and they have intrinsic GTPase activity. It undergoes a continuous cycle of de- and re-palmitoylation, which regulates its rapid exchange between the plasma membrane and the Golgi apparatus. Defects in HRAS are the cause of faciocutaneoskeletal syndrome (FCSS). FCSS is arare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities, tumor predisposition, skin and musculoskeletal abnormalities. Defects in HRAS also can cause congenital myopathy with excess of muscle spindles. HRAS deficiency may be a cause of susceptibility to Hurthle cell thyroid carcinoma. It has been shown that defects in HRAS can cause susceptibility to bladder cancer which is a malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas. They begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences. Defects in HRAS are the cause of oral squamous cell carcinoma.